Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237443 | 0.84 | POLB (0.53) | ALDH1A1MAPTKMT2AGAATP53 | |
| SCHEMBL7481528 | 0.84 | KDM4E (0.45) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL15057277 | 0.81 | KMT2A (0.52) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL3096202 | 0.81 | CA9 (0.57) | MAPTKMT2AGAATP53 | |
| SCHEMBL18865871 | 0.81 | KMT2A (0.52) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL3831470 | 0.78 | KMT2A (0.52) | ALDH1A1MAPTKMT2AGAATP53 | |
| SCHEMBL6049412 | 0.77 | ALDH1A1 (0.59) | MYCNR4A1ALDH1A1SMN1; SMN2GABRB2 | |
| SCHEMBL15529788 | 0.77 | SLC34A1 (0.43) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL17782460 | 0.76 | MYC (0.52) | MYCNR4A1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3299372 | 0.75 | KMT2A (0.68) | ALDH1A1MAPTKMT2AGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| WO-2013096049-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096060-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096051-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096051-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096049-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096060-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096055-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096055-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096059-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096059-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MYC 170/4885NR4A1 3693/4885ALDH1A1 3656/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MYC 220/4885NR4A1 3829/4885ALDH1A1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.